Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biohit Oyj Announces Results of GastroPanel Screening in Cooperation with Medical Center of the President's Affairs Administration of the Republic of Kazakhstan


Friday, 19 Apr 2013 02:30am EDT 

Biohit Oyj announced that the GastroPanel screening study started by Biohit Oyj and the Medical Center of the President's Affairs Administration of the Republic of Kazakhstan in the autumn of 2012 has been completed. The initial findings are encouraging. The Kazakhstan pilot project has a data sample of over 830 patients, which has been carefully examined and analyzed. Based on the results of the GastroPanel examination, less than 30% of the examined persons had an entirely normal stomach mucosa. Even more significant was the finding that the stomach mucosa of more than 17% of the patients was inflicted by advanced-stage atrophic gastritis. Because atrophic gastritis is the single most important risk factor for stomach cancer, these individuals should undergo an urgent gastroscopy examination due to the high risk of stomach cancer. This is not necessary, however, for the rest (almost 83%) of the examined individuals, because for them the GastroPanel examination is sufficient to inform the doctor that no alarming changes have taken place on the stomach mucosa. 

Company Quote

4.87
 --
18 Dec 2014